Study S001834

Adipose Tissue Heterogeneity and Its Link to Type 2 Diabetes: A Randomized Open Intervention Study That Compares Empagliflozin, Pioglitazone and Semaglutide

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT05501483
Acronym: DiaSpax
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Masking: NONE
Status: RECRUITING
Enrollment: 60
Start: 2023-02-08
Primary completion: 2026-09-01
Lead sponsor: Karolinska Institutet
Conditions: Type 2 Diabetes
Interventions: DRUG:Pioglitazone 45 mg; DRUG:Empagliflozin 25 MG; DRUG:Semaglutide 7 MG
Results posted: FALSE
Individual participant data sharing: NO
Secondary identifiers: OTHER_GRANT:2022-00792 and 2024-03434; EUDRACT_NUMBER:2021-002367-21

Registered primary outcomes

Changes in fat cell lipolysis after 6 months of treatment [Baseline and after six months intervention]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.